Change over period: —
NSE · ACCPL
Accretion Pharmaceuticals Ltd
Operates in pharmaceutical manufacturing and marketing. Develops formulations across therapeutic categories. Business model includes contract manufacturing and branded generics. Revenue is earned through product sales to distributors. Focuses on compliance-driven production. Serves domestic healthcare markets.
The short version. Promoter holding was 73.52% in Sep 2026, up 0.02 points over 6 quarters.
1 · The price
How has the stock traded?
4 · The owners
Who holds it, and are they adding?
Up 0.02 pts over 6 quarters.
Down 2.05 pts over 6 quarters.
Up 3.56 pts over 6 quarters.
+0 versus the previous month.
Shareholding pattern (%)
Quarter by quarter
| Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Change | |
|---|---|---|---|---|---|---|---|
| Promoter | 73.5 | 73.52 | 73.52 | 73.52 | 73.52 | 73.52 | +0.02 |
| FII | 2.22 | 1.16 | 0 | 0 | 0 | 0.17 | -2.05 |
| DII | 0.09 | 0 | 0 | 0 | 2.76 | 3.65 | +3.56 |
| Public | 24.19 | 25.33 | 26.48 | 26.48 | 23.72 | 22.66 | -1.53 |
Mutual fund holdings · Oct 2026
0 schemes hold this stock
0 the month before.
5 · The model view
What does our factor model say?
Factor scores, model flags and screen results for Accretion Pharmaceuticals Ltd are part of the Wright portfolio review.
Run your free portfolio reviewWatchouts
What to review
Model flags are shown inside the portfolio review, alongside your other holdings.
Related stocks
Other Pharmaceuticals & Biotechnology stocks
Quick answers
Common questions about Accretion Pharmaceuticals Ltd
What is the Accretion Pharmaceuticals Ltd share price?
Accretion Pharmaceuticals Ltd (ACCPL) last closed at ₹201.55, up 0.0% on the day.
What is the market cap of Accretion Pharmaceuticals Ltd?
Accretion Pharmaceuticals Ltd has a market capitalisation of about ₹224 crore. Its price-to-earnings ratio is 17.1.
How are Accretion Pharmaceuticals Ltd's latest results?
Promoter holding was 73.52% in Sep 2026, up 0.02 points over 6 quarters.
Who owns Accretion Pharmaceuticals Ltd?
As of Sep 2026, shareholding was: Promoter 73.52%, FII 0.17%, DII 3.65%, Public 22.66%.
How many mutual funds hold Accretion Pharmaceuticals Ltd?
0 mutual fund schemes held Accretion Pharmaceuticals Ltd in October 2026. That compares with 0 the month before.
Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.